Series A investors Pfizer Venture Investments and Roche Venture Fund have returned for a $10m round three years later.

Alexandria Venture Investments led a series C round that included existing investors Pfizer Ventures and Roche Venture Fund.

Blue Cross Blue Shield of Massachusetts and Blue Cross and Blue Shield of Kansas both backed a round that boosted the heart monitor developer's total financing to $77m.

The GlaxoSmithKline-backed immunotherapy developer closed an oversubscribed round that took its total funding to approximately $226m.

Elevian will commercialise research from Harvard and Stanford indicating young blood cells could be used to restore tissues in older patients.

Helsinn Investment Fund and Alexandria Venture Investments both invested as MD Anderson-backed OncoResponse looks to advance five immuno-oncology drug candidates.

Suono Bio is based on MIT research and is aiming to use low-frequency ultrasound to bring therapeutic compounds to target cells with greater efficiency.

Helsinn Investment Fund and Alexandria Venture Investments both invested as OncoResponse looks to advance five immuno-oncology drug candidates.

Cricket Health, developer of an integrated kidney care service that helps patients stay out of hospital, has completed an Oak HC/FT-led series A round.